New drug aims to deepen remission in multiple myeloma
Disease control
Completed
This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…
Phase: PHASE2 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC